Encapsulation and cardiac differentiation of hiPSCs in 3D PEG-fibrinogen hydrogels
The present invention relates to the production of cell cultures and tissues from undifferentiated pluripotent stem cells using three-dimensional biomimetic materials. The resultant cell cultures or tissues can be used in any of a number of protocols including testing chemicals, compounds, and drugs. Further, the methods and compositions of the present invention further provide viable cell sources and novel cell delivery platforms that allow for replacement of diseased tissue and engraftment of new cardiomyocytes from a readily available in vitro source. The present invention includes novel methods required for the successful production of cell cultures and tissues, systems and components used for the same, and methods of using the resultant cell and tissue compositions.
1. A method of producing a three-dimensional cardiac tissue comprising:
combining a population of pluripotent stem cells (PSCs) with a hydrogel precursor solution to form a PSC suspension, the hydrogel precursor solution comprising an acrylate component and a natural hydrogel-forming component comprising one or more of fibrinogen, collagen, gelatin, hyaluronic acid, elastin, fibronectin, laminin, fibrin, alginate, and decellularized cardiac extracellular matrix;
treating the PSC suspension by cross-linking to produce a three-dimensional PSC microenvironment; and
culturing the three-dimensional PSC microenvironment to differentiate the PSCs into a cardiac tissue.
2. The method of claim 1 , wherein treating the PSC suspension further comprises placing the PSC suspension into a mold prior to cross-linking.
3. The method of claim 1 , wherein the three-dimensional PSC microenvironment is selected from the group consisting of microislands, cardiac discs, strings, macrotissues, and microspheres, and combinations thereof.
4. The method of claim 1 , wherein treating the PSC suspension to produce a three-dimensional PSC microenvironment comprises covalently cross-linking the hydrogel precursor solution.
5. The method of claim 4 , wherein covalently cross-linking the hydrogel precursor solution comprises photo-crosslinking the hydrogel precursor solution.
6. The method of claim 5 , wherein the hydrogel precursor solution comprises an accelerator and at least one photoinitiator component.
7. The method of claim 6 , wherein the accelerator comprises triethanolamine (TEOA) and the at least one photoinitiator component comprises Eosin Y.
8. The method of claim 1 wherein the PSCs are human induced PSCs (hiPSCs).
9. The method of claim 1 , wherein the natural hydrogel-forming component is fibrinogen, and combining the population of PSCs with a hydrogel precursor solution comprises combining from 30 to 60 million PSCs per milliliter of hydrogel precursor solution.
10. The method of claim 1 , wherein culturing the three-dimensional PSC microenvironment to differentiate the PSCs into cardiac tissue does not include electrically or mechanically stimulating the three-dimensional PSC microenvironment.
11. The method of claim 1 , wherein the hydrogel precursor solution comprises acrylated PEG and fibrinogen.
12. The method of claim 1 , wherein the acrylate component comprises acrylated gelatin.
13. The method of claim 1 , wherein the acrylate component comprises a PEG-diacrylate.
14. The method of claim 1 , wherein treating the PSC suspension by cross-linking to produce a three-dimensional PSC microenvironment further comprises cross-linking until the three-dimensional PSC microenvironment reaches a stiffness of less than 500 Pascals.
15. The method of claim 14 , further comprising cross-linking until the three-dimensional PSC microenvironment reaches a stiffness of from 38 to 292 Pascals.